1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
The anti-tumor effect of the quinoline-3-carboxamide tasquinimod : Blockade of recruitment of CD11b+ Ly6Chi cells to tumor tissue reduces tumor growth
(
- Contribution to journal › Article
- 2015
-
Mark
S100A9 expressed in ER(-)PgR(-) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival.
(
- Contribution to journal › Article
- 2014
-
Mark
Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
(
- Contribution to journal › Article
-
Mark
High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome.
(
- Contribution to journal › Article
- 2012
-
Mark
S100A9 and tumor growth.
(
- Contribution to journal › Article
- 2010
-
Mark
Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors
(
- Contribution to journal › Article
- 2004
-
Mark
Frequent activation of CArG binding factor-A expression and binding in N-methyl-N-nitrosourea-induced rat mammary carcinomas
(
- Contribution to journal › Article
- 2002
-
Mark
Mechanism of action for N-substituted benzamide-induced apoptosis.
(
- Contribution to journal › Article
- 1993
-
Mark
Analysis of somatic mutation activity in multiple V kappa genes involved in the response to 2-phenyl-5-oxazolone
(
- Contribution to journal › Article